Oral administration of sophoricoside (SOP) inhibits neuronal damage and neuroinflammation to curb neurodegeneration in Parkinson's disease
- 21 September 2023
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 384, 110726
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- The Ameliorative Effect of Sophoricoside on Mast Cell-Mediated Allergic Inflammation in Vivo and in VitroMolecules, 2013
- Mitochondria and Programmed Cell Death in Parkinson's Disease: Apoptosis and BeyondAntioxidants & Redox Signaling, 2012
- NF-κB cellular and molecular regulatory mechanisms and pathways: Therapeutic pattern or pseudoregulation?Cellular Immunology, 2011
- Selectivity of the NF- B ResponseCold Spring Harbor Perspectives in Biology, 2009
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- Effects of sophoricoside and genistein on biological characteristics of osteoblastsJournal of Chinese Integrative Medicine, 2009
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Anti-Inflammatory Action of Legume Isoflavonoid Sophoricoside through Inhibition on Cyclooxygenase-2 ActivityPlanta Medica, 2003
- Anti-inflammatory mode of isoflavone glycoside sophoricoside by inhibition of lnterleukin-6 and cyclooxygenase-2 in inflammatory responseArchives of Pharmacal Research, 2003
- Association of circulating TNF-α and IL-6 with ageing and parkinsonismActa Neurologica Scandinavica, 1999